Title : Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Pub. Date : 2010 Feb 10

PMID : 20065189






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 This open-label, phase II study assessed the efficacy of vandetanib, a selective oral inhibitor of RET, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, in patients with advanced hereditary MTC. vandetanib epidermal growth factor receptor Homo sapiens